Nikko Asset Management Americas Inc. Sells 155,734 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Nikko Asset Management Americas Inc. lowered its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 4.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,992,663 shares of the company’s stock after selling 155,734 shares during the quarter. Nikko Asset Management Americas Inc. owned 2.94% of Intellia Therapeutics worth $34,894,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 2.3% in the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after purchasing an additional 280,946 shares during the last quarter. State Street Corp boosted its stake in shares of Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Intellia Therapeutics during the 4th quarter worth $43,177,000. Geode Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after acquiring an additional 49,367 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of Intellia Therapeutics by 5.0% during the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company’s stock worth $48,077,000 after acquiring an additional 111,104 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 29,000 shares of company stock valued at $352,551 over the last ninety days. Corporate insiders own 3.20% of the company’s stock.

Analyst Ratings Changes

NTLA has been the topic of several analyst reports. Oppenheimer dropped their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. William Blair restated a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. HC Wainwright initiated coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price target on the stock. Citigroup boosted their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company lowered their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Trading Down 0.9 %

Shares of Intellia Therapeutics stock opened at $9.14 on Monday. The firm has a market capitalization of $946.15 million, a price-to-earnings ratio of -1.68 and a beta of 1.97. Intellia Therapeutics, Inc. has a 12-month low of $8.30 and a 12-month high of $28.54. The firm’s 50 day simple moving average is $10.36 and its two-hundred day simple moving average is $14.59.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.